ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Brege Laura | Director | Jan 12 | Option Exercise | 17.01 | 12,500 | 212,625 | 12,500 | Jan 17 05:17 PM | BAKER BROS. ADVISORS LP | Director | Jan 12 | Option Exercise | 5.22 | 30,000 | 156,600 | 38,484,981 | Jan 17 04:22 PM | Brege Laura | Director | Jan 12 | Sale | 18.25 | 12,500 | 228,125 | 0 | Jan 17 05:17 PM | DAVIS STEPHEN | CEO | Jan 09 | Sale | 17.13 | 3,904 | 66,877 | 84,633 | Jan 10 08:38 PM | KIM AUSTIN D. | EVP,General Counsel, Secretary | Jan 09 | Sale | 17.13 | 589 | 10,090 | 18,697 | Jan 10 08:20 PM | Teehan Brendan | EVP, COO, Head of Commercial | Jan 09 | Sale | 17.13 | 532 | 9,113 | 4,549 | Jan 10 08:30 PM | Stankovic Srdjan R. | President | Nov 21 | Sale | 15.07 | 1,847 | 27,834 | 61,234 | Nov 22 04:34 PM | Stankovic Srdjan R. | President | Oct 15 | Sale | 15.81 | 1,326 | 20,964 | 56,831 | Oct 18 09:22 PM | DAVIS STEPHEN | CEO | Oct 15 | Sale | 15.81 | 2,804 | 44,331 | 79,009 | Oct 18 09:16 PM | Schneyer Mark C. | EVP, Chief Financial Officer | Jun 09 | Sale | 17.91 | 653 | 11,695 | 3,342 | Jun 10 08:51 PM | Schneyer Mark C. | EVP, Chief Financial Officer | Jun 08 | Option Exercise | 0.00 | 1,893 | 0 | 3,995 | Jun 10 08:51 PM | DAVIS STEPHEN | CEO | May 02 | Sale | 18.18 | 5,483 | 99,691 | 75,875 | May 03 08:58 PM | Stankovic Srdjan R. | President | May 02 | Sale | 18.18 | 2,865 | 52,091 | 55,188 | May 03 08:55 PM | KIM AUSTIN D. | EVP,General Counsel, Secretary | May 02 | Sale | 18.18 | 894 | 16,255 | 16,742 | May 03 08:51 PM | Teehan Brendan | EVP, COO, Head of Commercial | May 02 | Sale | 18.18 | 552 | 10,036 | 3,437 | May 03 08:47 PM | Kihara James | Principal Accounting Officer | Apr 08 | Sale | 27.05 | 1,025 | 27,726 | 2,433 | Apr 11 08:02 PM | Stankovic Srdjan R. | President | Feb 23 | Option Exercise | 0.00 | 4,919 | 0 | 49,938 | Feb 25 05:41 PM | Teehan Brendan | EVP, COO, Head of Commercial | Feb 23 | Option Exercise | 0.00 | 1,106 | 0 | 2,894 | Feb 25 05:45 PM | Kihara James | Principal Accounting Officer | Feb 23 | Option Exercise | 0.00 | 840 | 0 | 840 | Feb 25 05:45 PM | DAVIS STEPHEN | CEO | Feb 23 | Option Exercise | 0.00 | 10,945 | 0 | 69,661 | Feb 25 05:40 PM | KIM AUSTIN D. | EVP & General Counsel | Feb 23 | Option Exercise | 0.00 | 2,213 | 0 | 15,413 | Feb 25 05:42 PM | Teehan Brendan | EVP, COO, Head of Commercial | Feb 23 | Sale | 23.80 | 472 | 11,234 | 2,422 | Feb 25 05:45 PM | Stankovic Srdjan R. | President | Feb 23 | Sale | 23.80 | 1,501 | 35,724 | 48,437 | Feb 25 05:41 PM | Kihara James | Principal Accounting Officer | Feb 23 | Sale | 23.80 | 359 | 8,544 | 481 | Feb 25 05:45 PM | KIM AUSTIN D. | EVP & General Counsel | Feb 23 | Sale | 23.80 | 782 | 18,612 | 14,631 | Feb 25 05:42 PM | DAVIS STEPHEN | CEO | Feb 23 | Sale | 23.80 | 3,928 | 93,486 | 65,733 | Feb 25 05:40 PM |
|